Education
About Us
Working with TipRanks
Follow Us
Spyre Therapeutics (SYRE)
NASDAQ:SYRE
Total Valuation
Spyre Therapeutics has a market cap or net worth of $784.55M. The enterprise value is $839.17M.
Market Cap$784.55M
Enterprise Value$839.17M
Share Statistics
Spyre Therapeutics has 60.26M shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding60.26M
Owned by Insiders9.67%
Owned by Instutions50.52%
Financial Efficiency
Spyre Therapeutics’s return on equity (ROE) is -0.40 and return on invested capital (ROIC) is -37.61%.
Return on Equity (ROE)-40.17%
Return on Assets (ROA)-34.19%
Return on Invested Capital (ROIC)-37.61%
Return on Capital Employed (ROCE)-37.62%
Revenue Per Employee$0
Profits Per Employee-$3,200,276.923
Employee Count65
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Spyre Therapeutics is -41.90. Spyre Therapeutics’s PEG ratio is 0.42.
PE Ratio-41.90
PS Ratio0.00
PB Ratio16.83
Price to Fair Value16.83
Price to FCF-55.37
Price to Operating Cash Flow-55.37
PEG Ratio0.42
Income Statement
In the last 12 months, Spyre Therapeutics had revenue of $0.00 and earned -$208.02M in profits. Earnings per share was -$3.41.
Revenue$0.00
Gross Profit$0.00
Operating Income-$208.57M
Pretax Income-$207.97M
Net Income-$208.02M
EBITDA-208.57M
Earnings Per Share (EPS)-3.41
Cash Flow
In the last 12 months, operating cash flow was -$157.41M and capital expenditures $0.00, giving a free cash flow of -$157.41M billion.
Operating Cash Flow-$157.41M
Free Cash Flow-$157.41M
Free Cash Flow per Share-$2.61
Dividends & Yields
Spyre Therapeutics pays an annual dividend of , resulting in a dividend yield of
Dividend Per Share
Dividend Yield
Payout Ratio
Free Cash Flow Yield-1.81%
Earnings Yield-2.39%
Stock Price Statistics
Beta1.13
52-Week Price Change-62.96%
50-Day Moving Average18.49
200-Day Moving Average25.38
Relative Strength Index (RSI)35.50
Average Volume (3m)811.60K
Important Dates
Spyre Therapeutics upcoming earnings date is May 8, 2025, TBA.
Last Earnings DateFeb 27, 2025
Next Earnings DateMay 8, 2025
Ex-Dividend Date―
Financial Position
Spyre Therapeutics as a current ratio of 11.26, with Debt / Equity ratio of 0.00
Current Ratio11.26
Quick Ratio11.26
Debt to Market Cap0.00
Net Debt to EBITDA0.43
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Spyre Therapeutics has paid -$13.00K in taxes.
Income Tax-$13.00K
Effective Tax Rate0.02%
Enterprise Valuation
Spyre Therapeutics EV to EBITDA ratio is -41.36, with an EV/FCF ratio of -54.80.
EV to Sales0.00
EV to EBITDA-41.36
EV to Free Cash Flow-54.80
EV to Operating Cash Flow-54.80
Balance Sheet
Spyre Therapeutics has $603.09M in cash and marketable securities with $0.00 in debt, giving a net cash position of -$603.09M billion.
Cash & Marketable Securities$603.09M
Total Debt$0.00
Net Cash-$603.09M
Net Cash Per Share-$10.01
Tangible Book Value Per Share$1.38
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Spyre Therapeutics is $54.67, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$54.67
Price Target Upside330.13%
Analyst ConsensusStrong Buy
Analyst Count8
Revenue Growth Forecast-100.00%
EPS Growth Forecast94.68%